



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbszilpa.com, Web: www.vbszilpa.com
CIN: L85110KA1987PLC008739

Dated: September 1, 2023

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Pharma Lifesciences Ltd, Unit II, Raichur, Karnataka has cleared PMDA Japan, GMP inspection

This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by PMDA, Japan starting 29th August 2023. The inspection has concluded successfully on 1st September 2023 without any critical/major observation.

The facility is involved in manufacturing various oncology and non-oncology APIs.

The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.

With Regards,

For **SHILPA MEDICARE LIMITED**

Ritu Tiwary
Company Secretary & Compliance Officer